Empowered Patient Podcast

Daniel Hart, CEO of Sentact, describes the need to integrate technology, analytics, and services for hospitals and health systems to improve patient safety, patient outcomes, and regulatory readiness. One of Sentact's key goals is to help organizations gain insights from data to allow them to move from a reactive posture using lagging indicators to a proactive environment supported by AI and real-time data to generate early warning signals. Successful implementation of these insights also reduces operational costs and potentially eases clinician burnout.

Daniel explains, "Sentact is a healthcare technology, services, and analytics company. Three core pillars of our business are across tech analytics and services. We serve the hospital and health system market primarily, although we do have all types of healthcare organizations in our customer base. But as an example, a representative example, we service 60% of the top 20 health systems in the market with our solutions. And we are focused on patient safety, quality, experience, and regulatory readiness or compliance. That's the corner of healthcare in which we play."

"We offer a range of services through the combination of several companies over the last 12 to 18 months. And we're really excited about the integrated platform that we have compiled. And that platform extends from the credentialing function at a hospital to comprehensive rounding to support safety experience and compliance initiatives. It also includes clinical analytics to help manage provider performance and patient safety, to provide the necessary protections of safety information, and promote continuous learning."

#Sentact #HealthcareQuality #HealthcareTechnology #PatientSafety #HealthcareInnovation #DigitalHealth #HealthIT #PatientExperience #PatientOutcomes #HealthcareAnalytics #ClinicalOperations #RegulatoryCompliance #HealthSystemManagement #RiskManagement #QualityOutcomes

Sentact.com

Listen to the podcast here

Daniel Hart, CEO of Sentact, describes the need to integrate technology, analytics, and services for hospitals and health systems to improve patient safety, patient outcomes, and regulatory readiness. One of Sentact's key goals is to help organizations gain insights from data to allow them to move from a reactive posture using lagging indicators to a proactive environment supported by AI and real-time data to generate early warning signals. Successful implementation of these insights also reduces operational costs and potentially eases clinician burnout.

Daniel explains, "Sentact is a healthcare technology, services, and analytics company. Three core pillars of our business are across tech analytics and services. We serve the hospital and health system market primarily, although we do have all types of healthcare organizations in our customer base. But as an example, a representative example, we service 60% of the top 20 health systems in the market with our solutions. And we are focused on patient safety, quality, experience, and regulatory readiness or compliance. That's the corner of healthcare in which we play."

"We offer a range of services through the combination of several companies over the last 12 to 18 months. And we're really excited about the integrated platform that we have compiled. And that platform extends from the credentialing function at a hospital to comprehensive rounding to support safety experience and compliance initiatives. It also includes clinical analytics to help manage provider performance and patient safety, to provide the necessary protections of safety information, and promote continuous learning."

#Sentact #HealthcareQuality #HealthcareTechnology #PatientSafety #HealthcareInnovation #DigitalHealth #HealthIT #PatientExperience #PatientOutcomes #HealthcareAnalytics #ClinicalOperations #RegulatoryCompliance #HealthSystemManagement #RiskManagement #QualityOutcomes

Sentact.com

Download the transcript here

Matt Holland is Chief Operating Officer at Healio, a company that has been producing high-quality, vetted information for healthcare professionals for over 100 years. The company has focused on personalization of data as it has evolved from print to digital to AI-driven access to on-demand information. Healio AI is also transforming continuing medical education from a static activity to a dynamic, personalized experience based on real-time information gaps.

Matt explains, "We're a little bit unique in this space. We're family-owned and privately held, and have been for over a hundred years. So there are a lot of companies in this market right now that are not. So for decades, the focus has really been on developing and delivering quality information to healthcare professionals through all sorts of different channels. Obviously, prior to the internet, it started with good publications and journals. We also have a series of live meetings and conferences, but the primary focus really is the Healio AI, which we launched and evolved, and have been evolving, I should say, for the past 13 years or so."

"We just announced the Physician Advisory Board the other day. We just announced that physicians can get credit for CME and CV credits for their searches. And the reason why I mention that is physicians are no longer looking to necessarily read a full article or go into a deep dive on a particular topic. They're looking for an answer to a question they may have either prior to the point of care, during the point of care, or after. And we all know that their time is precious, and obviously, the issue of burnout is pretty pervasive. So, our goal is really to help make their lives simpler and improve the quality of their practice and the delivery of the care that they provide."

"We are a publishing news organization, and every day we develop 50-60 pieces of content from the FDA or from conferences or new studies that were released, and that's going into our model every 24 hours. So, there's sort of a deep dive substantive piece with the peer-reviewed and the journal content. There's a recency component to it with our news that goes into it, which makes the Healio AI a little bit different and we think unique, and I think balances and then hopefully more accurately and quickly addresses the questions that healthcare professionals have."

#Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare

Healio.com

Listen to the podcast here

Matt Holland is Chief Operating Officer at Healio, a company that has been producing high-quality, vetted information for healthcare professionals for over 100 years. The company has focused on personalization of data as it has evolved from print to digital to AI-driven access to on-demand information. Healio AI is also transforming continuing medical education from a static activity to a dynamic, personalized experience based on real-time information gaps.

Matt explains, "We're a little bit unique in this space. We're family-owned and privately held, and have been for over a hundred years. So there are a lot of companies in this market right now that are not. So for decades, the focus has really been on developing and delivering quality information to healthcare professionals through all sorts of different channels. Obviously, prior to the internet, it started with good publications and journals. We also have a series of live meetings and conferences, but the primary focus really is the Healio AI, which we launched and evolved, and have been evolving, I should say, for the past 13 years or so."

"We just announced the Physician Advisory Board the other day. We just announced that physicians can get credit for CME and CV credits for their searches. And the reason why I mention that is physicians are no longer looking to necessarily read a full article or go into a deep dive on a particular topic. They're looking for an answer to a question they may have either prior to the point of care, during the point of care, or after. And we all know that their time is precious, and obviously, the issue of burnout is pretty pervasive. So, our goal is really to help make their lives simpler and improve the quality of their practice and the delivery of the care that they provide."

"We are a publishing news organization, and every day we develop 50-60 pieces of content from the FDA or from conferences or new studies that were released, and that's going into our model every 24 hours. So, there's sort of a deep dive substantive piece with the peer-reviewed and the journal content. There's a recency component to it with our news that goes into it, which makes the Healio AI a little bit different and we think unique, and I think balances and then hopefully more accurately and quickly addresses the questions that healthcare professionals have."

#Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare

Healio.com

Download the transcript here

Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of new differentiation protocols and treatments for degenerative diseases.

Ryan explains, "The key problem that we are focused on applies to stem cell-derived cell therapies. And so, just for a little bit of context setting, we use induced pluripotent stem cells or IPS cells. And about 20 years ago, when these were first derived, everybody was very excited because this is the platform where you could then have an infinite supply of stem cells to then make any tissue-specific cell type at will, theoretically. Fast forward 20 years, and there are finally some cell therapies in phase three clinical trials, but none are approved yet. And that just tells you that the development cycle for this modality is actually slower than the other modalities, like biologics or small molecules. And the problem is manufacturing in particular, or how do you convert the stem cell into the target tissue cell type for the process of stem cell differentiation? And so we are solely focused on making stem cell differentiation an engineering problem rather than a kind of dark art."

"We have a program for type one diabetes that is making pancreatic beta cells from IPS cells. And we have also done some work in the musculoskeletal system. So these other cell types we focus on are more demonstrations of the platform technology, but we are interested in possibly co-developing those with other pharmaceutical partners, and that's the musculoskeletal cells of the hematopoietic system. And we've done some work on retinal cells as well, but we endeavor to make many other cell types. And our goal is to partner with the therapeutic experts in the area to develop these."

#SyntaxBio #CellTherapy #CRISPR #StemCells #Biotech #RegenerativeMedicine #Diabetes #Manufacturing #Innovation #GeneTherapy #LifeSciences #Bioengineering #SyntheticBiology #CellProgramming

syntax-bio.com

Listen to the podcast here

Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of new differentiation protocols and treatments for degenerative diseases.

Ryan explains, "The key problem that we are focused on applies to stem cell-derived cell therapies. And so, just for a little bit of context setting, we use induced pluripotent stem cells or IPS cells. And about 20 years ago, when these were first derived, everybody was very excited because this is the platform where you could then have an infinite supply of stem cells to then make any tissue-specific cell type at will, theoretically. Fast forward 20 years, and there are finally some cell therapies in phase three clinical trials, but none are approved yet. And that just tells you that the development cycle for this modality is actually slower than the other modalities, like biologics or small molecules. And the problem is manufacturing in particular, or how do you convert the stem cell into the target tissue cell type for the process of stem cell differentiation? And so we are solely focused on making stem cell differentiation an engineering problem rather than a kind of dark art."

"We have a program for type one diabetes that is making pancreatic beta cells from IPS cells. And we have also done some work in the musculoskeletal system. So these other cell types we focus on are more demonstrations of the platform technology, but we are interested in possibly co-developing those with other pharmaceutical partners, and that's the musculoskeletal cells of the hematopoietic system. And we've done some work on retinal cells as well, but we endeavor to make many other cell types. And our goal is to partner with the therapeutic experts in the area to develop these."

#SyntaxBio #CellTherapy #CRISPR #StemCells #Biotech #RegenerativeMedicine #Diabetes #Manufacturing #Innovation #GeneTherapy #LifeSciences #Bioengineering #SyntheticBiology #CellProgramming

syntax-bio.com

Download the transcript here

Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health monitoring through wearables and devices integrated into everyday life.

Daniel explains, "One of the things that imaging can do is peel away all of the obscuring layers of skin or skull or whatever else there is, without having to make a single cut, and show us the inner workings, show us inner space, what's inside. I think that means being able to detect tumors early enough that they can be cured, to guide surgeries, to try to understand what normal anatomy is, and exactly when it turns abnormal. So I think the ability to see what was once invisible has become so much a part of medicine that it's almost hard to imagine it without it."

"There are many analogies between inner space and outer space, and between the tools we have built as humans over the millennia to inspect them. I guess what I'd say, though, is that somehow the inspection of inner space, that sort of medical imaging for understanding our health, is a little bit more intimate. It causes us to ask very personal questions like, " Am I okay? Are my kids okay? Am I normal? What is normal? I think when we look at other types of imaging, imaging the world around us, imaging the cosmos a great distance from us, there are also existential questions, but it's really more, where do I fit in the big picture? So I think in some ways medical imaging picks up where, say, astronomical imaging leaves off and leaves us wondering who we are and how we're built."

#DanielSodickson #FutureofSeeing #FunctionHealth #AIHealthcare #MedicalImaging #HealthTech #FunctionHealth #DigitalHealth #MRI #HealthcareInnovation #PatientEmpowerment #FutureOfMedicine #HealthcareAccessibility

functionhealth.com

The Future of Seeing: How Imaging Is Changing Our World

Listen to the podcast here

Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health monitoring through wearables and devices integrated into everyday life.

Daniel explains, "One of the things that imaging can do is peel away all of the obscuring layers of skin or skull or whatever else there is, without having to make a single cut, and show us the inner workings, show us inner space, what's inside. I think that means being able to detect tumors early enough that they can be cured, to guide surgeries, to try to understand what normal anatomy is, and exactly when it turns abnormal. So I think the ability to see what was once invisible has become so much a part of medicine that it's almost hard to imagine it without it."

"There are many analogies between inner space and outer space, and between the tools we have built as humans over the millennia to inspect them. I guess what I'd say, though, is that somehow the inspection of inner space, that sort of medical imaging for understanding our health, is a little bit more intimate. It causes us to ask very personal questions like, " Am I okay? Are my kids okay? Am I normal? What is normal? I think when we look at other types of imaging, imaging the world around us, imaging the cosmos a great distance from us, there are also existential questions, but it's really more, where do I fit in the big picture? So I think in some ways medical imaging picks up where, say, astronomical imaging leaves off and leaves us wondering who we are and how we're built."

#DanielSodickson #FutureofSeeing #FunctionHealth #AIHealthcare #MedicalImaging #HealthTech #FunctionHealth #DigitalHealth #MRI #HealthcareInnovation #PatientEmpowerment #FutureOfMedicine #HealthcareAccessibility

functionhealth.com

The Future of Seeing: How Imaging Is Changing Our World

Download the transcript here

Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons. The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include earlier-stage and familial forms of the disease.

Howard explains, "Kenai was formed about three and a half years ago, and the intention is to develop a cellular product, which means that what is manufactured will be eligible in the right patient groups who have a diagnosis of Parkinson's to be placed into the brain. And consequent to its placement, the cells will then form new circuits, dopamine circuits that are lost owing to the disease diagnosis that will have occurred years earlier."

"The induced pluripotent stem cell approach is one we favor for several reasons. The nature of what then becomes the IPSC, as we like to call it, starts with a normal human volunteer whose medical history is very detailed and does not contain any familial personal history of neurodegeneration. That cell then undergoes a process called reprogramming. And in our case, it's done with a slightly different approach than many others. And the reprogramming effectively creates a cell that is pluripotent, meaning it can become any cell of the body. That's when it is designated as an induced pluripotent stem cell."

#KenaiTherapeutics #ParkinsonsDisease #CellTherapy #StemCells #Neuroscience #MedicalInnovation #ClinicalTrials #RegenerativeMedicine #Biotechnology #BioTech #AdvancedBiologics #NeurologicalDisorders #Neurology #DrugDevelopment

KenaiTx.com

Listen to the podcast here

Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons. The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include earlier-stage and familial forms of the disease.

Howard explains, "Kenai was formed about three and a half years ago, and the intention is to develop a cellular product, which means that what is manufactured will be eligible in the right patient groups who have a diagnosis of Parkinson's to be placed into the brain. And consequent to its placement, the cells will then form new circuits, dopamine circuits that are lost owing to the disease diagnosis that will have occurred years earlier."

"The induced pluripotent stem cell approach is one we favor for several reasons. The nature of what then becomes the IPSC, as we like to call it, starts with a normal human volunteer whose medical history is very detailed and does not contain any familial personal history of neurodegeneration. That cell then undergoes a process called reprogramming. And in our case, it's done with a slightly different approach than many others. And the reprogramming effectively creates a cell that is pluripotent, meaning it can become any cell of the body. That's when it is designated as an induced pluripotent stem cell."

#KenaiTherapeutics #ParkinsonsDisease #CellTherapy #StemCells #Neuroscience #MedicalInnovation #ClinicalTrials #RegenerativeMedicine #Biotechnology #BioTech #AdvancedBiologics #NeurologicalDisorders #Neurology #DrugDevelopment

KenaiTx.com

Download the transcript here